Alexander Zwyer has served as our Chief Executive Officer and as a Director since our incorporation in August 2015. Mr. Zwyer has over 25 years of international business experience. In 2007, prior to, and until founding NLS in 2015, Mr. Zwyer founded a startup in the high-end luxury food sector, and served as its chief executive officer until 2015 when he successfully sold the company. From 1991 and until 2007, Mr. Zwyer served in various positions with Viforpharma AG (SWX: VIFN) (then known as Vifor (International) Inc.), most notably serving as Executive Vice President (chief operations officer), leading the company’s global regulatory affairs, medical affairs, sales and marketing as well as business development teams. Mr. Zwyer speaks seven languages fluently. Mr. Zwyer holds a B.B.A. in business administration from Oekral, Zurich, Switzerland and an executive M.B.A. from GSBA/Lorange Institute of Business, Zurich, Switzerland and an M.B.A. from University at Albany SUNY.
|
Robert Dickey IV has served as our Interim Chief Financial Officer since August 2019, and previously served as our Deputy Chief Financial Officer from February 2019. Mr. Dickey has over 25 years of experience leading life science and medical device companies, both private and public. Mr. Dickey currently serves as the Managing Director of Danforth Advisors, through which he is engaged with us. Prior to his joining Danforth Advisors, Mr. Dickey served as Chief Financial Officer of several companies, including Mofit Bio PLC (Nasdaq/AIM: MTFB), Tyme Technologies (Nasdaq: TYME) from 2017 to 2018 and NeoStem, Inc. (now, Caladrius Biosciences) (Nasdaq: CLBS) from 2013 to 2015. Since 2018, Mr. Dickey has served on the board of directors and as chairman of the audit committee of Emmaus Life Sciences, Inc. (Nasdaq: EMMA). Mr. Dickey previously spent 18 years in investment banking at Lehman Brothers and Legg Mason. Mr. Dickey holds a A.B. from Princeton University and M.B.A. from The Wharton School, University of Pennsylvania.
|